New Stock Offerings - Jichuan Pharmaceutical (600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - ST Yazhen (603389) has a tender offer period from June 10, 2025, to July 9, 2025[1] Delisting and Trading Reminders - ST Gongzhi (000584) will enter the delisting arrangement period starting June 20, 2025[1] - ST Jiuyou (600462) will enter the delisting arrangement period starting June 24, 2025[1] - Haiyue (600387) has 12 trading days remaining until the last trading day[1] - Renle (002336) has 11 trading days remaining until the last trading day[1] - Longyu (603003) has 8 trading days remaining until the last trading day[1] - Pengbo (600804) has 8 trading days remaining until the last trading day[1] - Longjin (002750) has 6 trading days remaining until the last trading day[1] Market Volatility - Lianhua Technology (002250) reported severe abnormal fluctuations[1] - ST Kailin (002425) and ST Xuefa (002485) also reported abnormal fluctuations[2]

Group 1 - The core point of the news is the announcement of a family internal equity structure adjustment at Jichuan Pharmaceutical, which triggers a mandatory general offer for the company's shares by Cao Fei, the son of the actual controller, Cao Longxiang [1][2] - On June 11, Cao Longxiang transferred 10.10% of his shares in Jichuan Holdings to Cao Fei for 10.1 million yuan, resulting in Cao Fei holding 60% of Jichuan Holdings and indirectly controlling 5.17 billion shares of Jichuan Pharmaceutical, which is 56.07% of the total share capital [1] - The general offer price is set at 26.93 yuan per share, requiring a maximum total funding of 9.448 billion yuan, with the offer period lasting from June 18, 2025, to July 17, 2025 [2] Group 2 - Jichuan Pharmaceutical's major shareholder structure remains unchanged after the transfer, with Jichuan Holdings holding 4.17 billion shares, accounting for 45.22% of the total share capital, and the combined holdings of the controlling shareholder and concerted parties reaching 61.15% [1] - The company reported a revenue of 1.525 billion yuan in the first quarter of 2025, a year-on-year decrease of 36.51%, and a net profit attributable to shareholders of 440 million yuan, down 47.91% year-on-year [3] - The decline in revenue is attributed to two main factors: a high base in the first quarter of 2024 and the impact of centralized procurement on the main product, Rabeprazole Sodium Enteric-coated Capsules [3]

Core Viewpoint - The announcement details Mr. Cao Fei's tender offer to acquire shares of Hubei Jichuan Pharmaceutical Co., Ltd., with a focus on the acquisition's timeline, purpose, and conditions [2][3][4]. Group 1: Tender Offer Details - The tender offer is valid from June 18, 2025, to July 17, 2025, with specific conditions regarding the withdrawal of acceptance in the last three trading days [2][6][9]. - Mr. Cao Fei intends to acquire 350,841,357 shares, representing 38.06% of the total share capital of the company, at a price of 26.93 yuan per share [5][6]. - The payment method for the tender offer will be in cash [4][5]. Group 2: Purpose of the Tender Offer - The tender offer is a result of a share transfer agreement between Mr. Cao Longxiang and Mr. Cao Fei, where 10.10% of Jiangsu Jichuan Holding Group Co., Ltd. was transferred to Mr. Cao Fei for 10.1 million yuan, indicating a family restructuring of shareholding [2][3]. - The acquisition aims to fulfill the legal obligation for a comprehensive tender offer, and it does not intend to terminate the listing status of Jichuan Pharmaceutical [3]. Group 3: Procedures for Acceptance - Shareholders can submit their acceptance of the tender offer through designated securities companies during the offer period, with specific codes for the tender offer [7][8]. - Accepted shares will be temporarily held by China Securities Depository and Clearing Corporation Limited during the offer period, and shareholders cannot transfer these shares until the withdrawal process is completed [8][10]. Group 4: Additional Information - The company will provide updates on the progress of the tender offer and will issue a results announcement after the offer period ends [6][13]. - Investors seeking detailed information can refer to the tender offer report published on June 16, 2025, on the Shanghai Stock Exchange website [15].

Group 1 - The actual controller of Jichuan Pharmaceutical, Cao Longxiang, is transferring shares to his son, Cao Fei, which triggers a mandatory tender offer for the company [1][2] - Cao Fei will acquire 351 million shares, representing 38.06% of the total issued shares, with a maximum transaction value of 9.448 billion yuan [1][2] - Following the share transfer, Cao Fei's stake in Jichuan Holdings will increase to 60%, allowing him to indirectly control 517 million shares of Jichuan Pharmaceutical, exceeding the 30% threshold for a mandatory tender offer [2] Group 2 - Jichuan Pharmaceutical is facing significant pressure, with revenue and net profit declining for four consecutive quarters due to price cuts from centralized procurement [4] - In 2024, the company expects to achieve revenue of 8.017 billion yuan, a year-on-year decrease of 16.96%, and a net profit of 2.532 billion yuan, down 10.32% [4] - The company's sales expenses are high at 2.954 billion yuan, accounting for 36.85% of total revenue, while R&D expenses are only 445 million yuan, representing 5.55% of total revenue [4]

Group 1 - Banqiao Qiancheng signed a significant contract with Mango Film and Television for a total amount of 372 million yuan, accounting for 50.65% of the company's audited main business income for 2024 [1] - The contract allows Mango Film and Television to use the new media and traditional media broadcasting rights for related film and television works globally, positively impacting Banqiao Qiancheng's financial status and operating performance in 2025 and beyond [1] - Jingwei Huikai plans to sell its wholly-owned subsidiary Changsha Yushun for 112 million yuan, which will no longer be included in the consolidated financial statements after the transaction [1] Group 2 - Minsheng Health's subsidiary received a patent for a strain of lactic acid bacteria that significantly improves sarcopenic obesity, although it has not yet been applied to the company's products [2] - Dafu Technology intends to transfer 27% of its subsidiary Shenzhen Peitian Intelligent Manufacturing Equipment Co., Ltd. for 192 million yuan, maintaining a controlling stake post-transaction [3] - Feilong Co. received orders for high-power electronic water pumps for data centers from a well-known global power electronics provider [4] Group 3 - Yatai Co. was selected as a supplier for a foreign brand's EPB project, with a total sales amount of approximately 680 million yuan over a five-year lifecycle [5] - Gansu Energy's 1 million kilowatt wind-solar integrated project has received approval, representing over 10% of the company's installed capacity by the end of 2024 [6] - Jilin Aodong's subsidiary received approval for a drug supplement application for "Tang Le Capsule," used to treat symptoms related to diabetes [7] Group 4 - Shanshui Technology plans to invest 6 billion yuan in a new chemical materials project, expected to generate an annual output value of 8 billion yuan upon completion [8] - Dazhu CNC's H-share issuance application has been accepted by the China Securities Regulatory Commission [9] - Zhujiang Beer announced the resignation of its chairman due to retirement age, with a new chairman elected on the same day [10] Group 5 - Longkun Technology won a bid for a waste collection service project worth 21.57 million yuan, with a service period of one year [11] - Zhongnan Culture plans to provide financial support of up to 20 million yuan to its subsidiary for daily operational needs [12] - Shangfeng Cement's investment in a company applying for an IPO on the Sci-Tech Innovation Board has been accepted [13] Group 6 - Chuanheng Co. received a patent for a system and method for harmless treatment of phosphorus tailings [14] - Toukeng Life's seven medical device registration applications have been accepted, covering various diagnostic fields [15] - Xingqi Eye Medicine's clinical trial for a new eye gel has commenced with the first subject enrolled [16] Group 7 - Jiebang Technology plans to provide financial support of up to 60 million yuan to its subsidiary for operational needs [17] - Shenzhen Airport reported a passenger throughput of 5.54 million in May, a year-on-year increase of 15.67% [18] - Wan'an Technology received a cash dividend of 30 million yuan from its wholly-owned subsidiary [19] Group 8 - Jiuchuan Bio received a medical device registration certificate for a cystatin C assay kit [20] - Hongqiang Co. obtained a safety production license for its subsidiary, marking the official production of a new project [21] - Xiangtan Electric plans to issue convertible bonds totaling 487 million yuan [22] Group 9 - Guangwei Composite signed a supplementary material procurement contract worth 658 million yuan [23] - Jichuan Pharmaceutical announced a comprehensive tender offer starting June 18, with a price of 26.93 yuan per share [24] - Aerospace Rainbow plans to distribute cash dividends of 0.60 yuan per share [25] Group 10 - Industrial Bank plans to distribute cash dividends of 1.06 yuan per share, totaling 22.433 billion yuan [26] - China Automotive Research will repurchase and cancel 230,800 restricted shares due to the retirement of original incentive objects [27] - Annie Co. announced abnormal stock trading fluctuations but confirmed no significant changes in its operations [28] Group 11 - Giant Network confirmed no undisclosed significant matters following abnormal stock trading fluctuations [29]

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-044 湖北济川药业股份有限公司 关于曹飞先生要约收购公司股份的第一次提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司于 2025 年 6 月 16 日披露了《湖北济川药业股份有限公司要约收购报告 书》，曹飞先生自 2025 年 6 月 18 日起要约收购公司股份 350,841,357 股。本次 要约收购的具体情况如下： 一、 本次要约收购的基本情况 1 本次公告为曹飞先生要约收购湖北济川药业股份有限公司（以下简称"上 市公司"或"公司"）股份的第一次提示性公告。 预受要约申报代码：706034，申报简称：济川收购 要约收购支付方式：现金 要约收购有效期：2025 年 6 月 18 日至 2025 年 7 月 17 日。按照本次要 约收购申报程序，本次要约收购期限届满前最后三个交易日（2025 年 7 月 15 日、2025 年 7 月 16 日、2025 年 7 月 17 日），预受股东不得撤回 其对要约的接受。 1.被收 ...

Group 1: New Stock Offerings - Jichuan Pharmaceutical (600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - *ST Yazhen (603389) has a tender offer period from June 10, 2025, to July 9, 2025[1] Group 2: Delisting Information - *ST Gongzhi (000584) will enter the delisting arrangement period starting June 20, 2025[1] - Delisting Haiyue (600387) has 14 trading days remaining until the last trading day[1] - Renle Tui (002336) has 13 trading days remaining until the last trading day[1] - Delisting Longyu (603003) has 10 trading days remaining until the last trading day[1] - Delisting Pengbo (600804) has 10 trading days remaining until the last trading day[1] - Longjin Tui (002750) has 8 trading days remaining until the last trading day[1] Group 3: Abnormal Fluctuations - Lianhua Technology (002250) reported severe abnormal fluctuations[1] - ST Kailin (002425) reported abnormal fluctuations[1] - ST Xianfeng (002141) reported abnormal fluctuations[1] - ST Shihuan (000518) reported abnormal fluctuations[1]

转自：咸宁新闻网 智能化建设作为企业高质量发展的核心引擎，亦是中医药行业现代化与标准化发展的根基。多年来，济川药业 坚持创新驱动变革发展，秉承品质至上的质量理念，在中成药的全流程生产中，深度融入智能技术，实现了从 仓储管理到生产环节的全面智能化升级，为中药产业的现代化发展注入了强劲动力。日前，济川药业集团有限 公司凭借"基于全生命周期可靠追溯的中药口服液智能工厂"项目成功入选2025年江苏省先进级智能工厂 在仓储管理智能化方面：济川药业通过引入堆垛机、机器人码盘机、箱输送机等自控设备，结合先进的 WMS(仓储管理系统)和WCS(仓储控制系统)，实现了药品存储、分拣及出入库全流程自动化作业。显著提升空 间利用率的同时，确保了库存数据的精准度，为生产计划的精准执行提供了有力保障。 在生产环节人机协同方面：在生产线上，济川药业整合了贴签、压塑、装盒、喷码、检重、装箱等全流程工 序，实现了人机协同作业与柔性生产。电眼实时监测产品触发贴标，视觉检测设备全程保障装盒质量，机械手 臂与智能设备紧密配合，确保了每一道工序的高效与精准。 在在线智能检测技术方面：济川药业引入了基于智能灯检机的在线智能检测技术，通过先进视觉成像技 ...

Group 1 - The core point of the news is the internal equity structure adjustment within the family of the actual controller of Jichuan Pharmaceutical, leading to a mandatory general offer for shares, initiated by Cao Fei, which does not aim to terminate the company's listing status [1] - The equity transfer involves Cao Longxiang transferring 10.10% of his shares in Jichuan Holdings to his son, Cao Fei, resulting in Cao Fei holding 60% of Jichuan Holdings and indirectly controlling 5.17 billion shares of the listed company, accounting for 56.07% of the total share capital [1] - The mandatory general offer will cover all freely tradable shares held by other shareholders, totaling 351 million shares, which is 38.06% of the company's total share capital, with an offer price of 26.93 yuan per share, valid for 30 days from June 18, 2025, to July 17, 2025 [1][2] Group 2 - The total maximum funding required for the general offer is approximately 94.48 billion yuan, sourced from the acquirer's own funds and legally raised funds, with 18.95 billion yuan deposited as a performance guarantee [2] - The transition of control from one generation to the next is a significant trend in the industry, with over 80% of private enterprises in China being family-owned, and many are currently undergoing generational handovers [2] - The company aims to maintain stable development of its core business while promoting innovation and transformation, focusing on a dual pillar layout of traditional Chinese medicine and chemical medicine, and accelerating the launch of new products through strategic cooperation and technology introduction [3]

Core Viewpoint - The company has received a takeover offer from Mr. Cao Fei, which triggers a mandatory general offer due to the increase in shareholding above 30% [2][4]. Summary by Sections Offer Details - The offer price is set at 26.93 yuan per share, with a total of 350,841,357 shares being offered, representing 38.06% of the company's issued shares [4][5]. - The offer period lasts for 30 days, from June 18, 2025, to July 17, 2025, during which shareholders cannot withdraw their acceptance in the last three trading days [7]. Shareholding Changes - Mr. Cao Longxiang plans to transfer 10.10% of his shares in Jiangsu Jichuan Holding Group to his son, Mr. Cao Fei, making Mr. Cao Fei the controlling shareholder of Jichuan Holding with 60% ownership [2][4]. - Following the transfer, both Mr. Cao Fei and Mr. Cao Longxiang will be the joint actual controllers of the listed company, ensuring that the company's independence remains unaffected [2][4]. Financial Arrangements - The total maximum funding required for the offer is 18.95 billion yuan, with at least 20% of this amount deposited as a performance guarantee [6]. - The funding for the offer comes from the acquirer's own funds and legally raised funds, with no involvement from the listed company or its affiliates [6][7]. Compliance and Procedures - The acquirer, Mr. Cao Fei, does not require any authorization or approval from relevant institutions to make the offer [4]. - The offer is made in compliance with the Securities Law and the Takeover Management Measures, ensuring that the offer price is based on the weighted average price of the company's shares over the previous 30 trading days [5].